Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Orelabrutinib Plus 4 Gy Radiotherapy Versus 24 Gy Radiotherapy for Stage I/II MALT Lymphoma

17 de novembro de 2026 atualizado por: Rong Tao, Fudan University

A Multicenter, Prospective, Phase II, Randomized Study of Orelabrutinib Plus 4 Gy Radiotherapy Versus 24 Gy Radiotherapy as First-Line Treatment for Patients With Stage I/II MALT Lymphoma

This is a multicenter, open-label, randomized, controlled phase II study evaluating the efficacy and safety of short-course orelabrutinib induction followed by low-dose involved-site radiotherapy (ISRT) compared with standard-dose ISRT in patients with previously untreated, limited-stage extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).

Visão geral do estudo

Descrição detalhada

Eligible patients will be randomized in a 1:1 ratio to either the experimental arm or the control arm. Patients in the experimental arm will receive oral orelabrutinib for 12 weeks followed by 4 Gy ISRT (2 Gy × 2 fractions), while patients in the control arm will receive 24 Gy ISRT (2 Gy × 12 fractions).

The primary endpoint is the 2-year progression-free survival (PFS) rate. Key secondary endpoints include the radiotherapy omission rate, 2-year event-free survival (EFS), complete response (CR) rate, objective response rate (ORR), in-field and out-of-field recurrence rates, safety, and quality of life (QoL).

Tipo de estudo

Intervencional

Inscrição (Estimado)

272

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200032
        • Fudan University Shanghai Cancer Center
        • Contato:
        • Contato:
          • Número de telefone: 8621-64175590
        • Investigador principal:
          • Rong Tao, MD&PhD
        • Investigador principal:
          • Yizhen Liu, MD&PhD
        • Investigador principal:
          • Xuejun Ma, MD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Age ≥18 years.
  • Histologically confirmed extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).
  • MALT lymphoma involving, but not limited to, the following sites: orbit, parotid gland, thyroid, Helicobacter pylori (H. pylori)-negative gastric MALT lymphoma, lung, intestine, prostate, and other sites.

For gastric MALT lymphoma, H. pylori negativity must be confirmed by a 13C-urea breath test or gastric mucosal histology. For patients with unknown prior H. pylori status who have previously received H. pylori eradication therapy, serum H. pylori antibody may remain positive. In such cases, at least 1 year must have elapsed since completion of eradication therapy, and repeat gastroscopy and/or breath testing must be negative. Patients with a history of H. pylori infection must have the eradication regimen documented. If t(11;18) testing is available, the result should also be documented for exploratory analysis.

  • Lugano stage I-II disease. Staging will be performed according to the Lugano classification. Limited-stage disease eligible for this study is defined as all known MALT lymphoma lesions being confined to a single organ or paired organs, with or without regional lymph node involvement, and all disease being safely amenable to coverage by limited-field curative-intent involved-site radiotherapy (ISRT).

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

  • Ability to understand and willingness to voluntarily provide written informed consent.

  • Adequate organ function, defined as follows:

    1. Hematologic function: absolute neutrophil count ≥1.0 × 10^9/L, platelet count ≥50 × 10^9/L, and hemoglobin ≥80 g/L.
    2. Hepatic function: total bilirubin ≤1.5 × the upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <3 × ULN, and serum albumin ≥30 g/L.
    3. Renal function: serum creatinine <1.5 × ULN and creatinine clearance ≥50 mL/min, calculated using the standard Cockcroft-Gault formula. For renal impairment caused by tumor compression, creatinine clearance ≥30 mL/min is acceptable.
    4. Coagulation function: unless the participant is receiving anticoagulant therapy and the coagulation parameters (PT/INR and APTT) are within the expected range for the anticoagulant treatment, international normalized ratio (INR) ≤1.5 × ULN and activated partial thromboplastin time (APTT) ≤1.5 × ULN.

Exclusion Criteria:

  • Major surgery within 4 weeks before enrollment, except for diagnostic surgery.

  • Uncontrolled concomitant diseases, including cardiovascular or cerebrovascular disease, coagulation disorders, and severe infectious diseases, including but not limited to:

    1. severe acute or chronic infections requiring systemic treatment;
    2. symptomatic congestive heart failure (New York Heart Association class III-IV);
    3. symptomatic or inadequately controlled arrhythmia;
    4. inadequately controlled arterial hypertension despite standard treatment (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg);
    5. unstable angina;
    6. active peptic ulcer disease or bleeding disorders.
  • Severe concomitant diseases that may interfere with routine treatment.

  • Known active interstitial pneumonia.

  • Viral hepatitis and other active infections:

    1. Active chronic hepatitis B infection, defined as positive hepatitis B virus (HBV) DNA. Patients with latent or prior HBV infection (defined as positive hepatitis B surface antigen [HBsAg] or total hepatitis B core antibody [HBcAb]) may be enrolled if HBV DNA is undetectable at screening. Such patients must be willing to undergo regular HBV DNA monitoring and receive appropriate antiviral therapy as required by the study.
    2. Patients with positive hepatitis C virus (HCV) antibody may participate only if HCV RNA is negative by polymerase chain reaction (PCR).
    3. Active infection with human immunodeficiency virus (HIV) or syphilis.
  • Pregnant or breastfeeding women.

  • Dysphagia or inability to take oral medication on a long-term basis.

  • Patients considered unsuitable for participation in the study by the investigator.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Orelabrutinib + 4 Gy ISRT

Participants will receive oral orelabrutinib for 12 weeks, followed by 4 Gy involved-site radiotherapy (ISRT), administered as 2 Gy per fraction for 2 fractions. Radiotherapy will be initiated within 4 weeks after completion of orelabrutinib. Response will be assessed after treatment, and additional local radiotherapy or salvage treatment may be administered according to the predefined response-based management strategy.

Orelabrutinib 150 mg orally once daily for 12 weeks. Dose interruption and reduction are permitted according to the protocol-defined toxicity management criteria.

Involved-site radiotherapy (ISRT) at a total dose of 4 Gy, delivered as 2 Gy in 2 fractions, following the ILROG-recommended technical framework for extranodal lymphoma and ISRT. Radiotherapy is initiated within 4 weeks after completion of orelabrutinib treatment.

Comparador Ativo: 24 Gy ISRT

Participants will receive 24 Gy involved-site radiotherapy (ISRT), administered as 2 Gy per fraction for 12 fractions. Radiotherapy will be initiated within 4 weeks after randomization. Patients with inadequate response may receive salvage treatment at the investigator's discretion.

Involved-site radiotherapy (ISRT) at a total dose of 24 Gy, delivered as 2 Gy in 12 fractions. Radiotherapy is initiated within 4 weeks after randomization.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
2-year Progression-Free Survival (PFS) Rate
Prazo: 2 years after randomization

Progression-free survival is defined as the time from randomization to the first documented disease progression or death from any cause. Participants without a PFS event at the data cutoff will be censored at the date of the last adequate tumor assessment. Additional 20 Gy radiotherapy administered according to the protocol-defined response-adapted treatment strategy is not considered a PFS event and will not result in censoring.

2 years after randomization

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Radiotherapy Omission Rate
Prazo: From randomization through 24 months

The proportion of participants in the experimental arm who receive no additional 20 Gy radiotherapy or other local salvage radiotherapy from randomization through 24 months. The denominator is the intent-to-treat population in the experimental arm, excluding participants who do not receive the planned 4 Gy radiotherapy. Participants who are lost to follow-up, receive radiotherapy outside the protocol, or receive other anti-lymphoma treatment are included in the denominator.

From randomization through 24 months
2-year Event-Free Survival (EFS) Rate
Prazo: 2 years after randomization

Event-free survival is defined as the time from randomization to the occurrence of any event, including discontinuation of orelabrutinib because of toxicity, failure to complete 4 Gy radiotherapy, death, disease relapse, disease progression, initiation of a new anti-lymphoma treatment, or additional radiotherapy.

2 years after randomization
Objective Response Rate (ORR)
Prazo: Throughout the treatment period, up to 2 years

The proportion of participants who achieve a complete response or partial response according to the study-defined response assessment criteria based on the Lugano 2014 framework, with site-specific adaptations for extranodal MALT lymphoma.

Throughout the treatment period, up to 2 years
Complete Response (CR) Rate
Prazo: Throughout the treatment period, up to 2 years

The proportion of participants who achieve a complete response according to the study-defined response assessment criteria based on the Lugano 2014 framework, with site-specific adaptations for extranodal MALT lymphoma.

Throughout the treatment period, up to 2 years
Local Recurrence Rate at the Irradiated Site
Prazo: From randomization through 24 months

The proportion of participants who develop disease recurrence at the previously irradiated site during follow-up.

From randomization through 24 months
Incidence of Adverse Events
Prazo: up to 2 years

Safety will be assessed by the incidence and severity of adverse events in participants who receive at least one dose of study treatment or at least one radiotherapy treatment. Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 6.0.

up to 2 years
Quality of life questionnaire(EORTC QLQ-C30)
Prazo: Up to 2 years

evaluate patients' quality of life by questionnaire using EORTC QLQ-C30.There are a total of 30 entries. Among them, items 29 and 30 are divided into seven levels, ranging from 1 to 7 points based on their answer options; The other items are divided into four levels: none, a little, many to many, and are rated directly on a scale of 1 to 4.

Up to 2 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Cadeira de estudo: Rong Tao, MD & PhD, Fudan University
  • Investigador principal: Xuejun Ma, MD, Fudan University
  • Investigador principal: Yizhen Liu, MD & PhD, Fudan University

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

18 de novembro de 2026

Conclusão Primária (Estimado)

31 de dezembro de 2031

Conclusão do estudo (Estimado)

30 de junho de 2032

Datas de inscrição no estudo

Enviado pela primeira vez

11 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

17 de novembro de 2026

Primeira postagem (Real)

18 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever